Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

G6PD deficiency: global distribution, genetic variants and primaquine therapy.

Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI.

Adv Parasitol. 2013;81:133-201. doi: 10.1016/B978-0-12-407826-0.00004-7. Review.

PMID:
23384623
2.

Mass primaquine treatment to eliminate vivax malaria: lessons from the past.

Kondrashin A, Baranova AM, Ashley EA, Recht J, White NJ, Sergiev VP.

Malar J. 2014 Feb 7;13:51. doi: 10.1186/1475-2875-13-51. Review.

3.

Management of relapsing Plasmodium vivax malaria.

Chu CS, White NJ.

Expert Rev Anti Infect Ther. 2016 Oct;14(10):885-900. doi: 10.1080/14787210.2016.1220304. Epub 2016 Aug 31. Review.

4.

Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.

Rajapakse S, Rodrigo C, Fernando SD.

Cochrane Database Syst Rev. 2015 Apr 29;(4):CD010458. doi: 10.1002/14651858.CD010458.pub2. Review.

5.

Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria.

Baird K.

Pathog Glob Health. 2015 May;109(3):93-106. doi: 10.1179/2047773215Y.0000000016. Review.

6.

Primaquine: the risks and the benefits.

Ashley EA, Recht J, White NJ.

Malar J. 2014 Nov 3;13:418. doi: 10.1186/1475-2875-13-418. Review.

7.

Primaquine treatment and relapse in Plasmodium vivax malaria.

Rishikesh K, Saravu K.

Pathog Glob Health. 2016;110(1):1-8. doi: 10.1080/20477724.2015.1133033. Epub 2016 Feb 18. Review.

8.

Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group.

Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, Sattabongkot J, Jambert E, Domingo GJ, Commons R, Auburn S, Marfurt J, Devine A, Aktaruzzaman MM, Sohel N, Namgay R, Drukpa T, Sharma SN, Sarawati E, Samad I, Theodora M, Nambanya S, Ounekham S, Mudin RN, Da Thakur G, Makita LS, Deray R, Lee SE, Boaz L, Danansuriya MN, Mudiyanselage SD, Chinanonwait N, Kitchakarn S, Nausien J, Naket E, Duc TN, Do Manh H, Hong YS, Cheng Q, Richards JS, Kusriastuti R, Satyagraha A, Noviyanti R, Ding XC, Khan WA, Swe Phru C, Guoding Z, Qi G, Kaneko A, Miotto O, Nguitragool W, Roobsoong W, Battle K, Howes RE, Roca-Feltrer A, Duparc S, Bhowmick IP, Kenangalem E, Bibit JA, Barry A, Sintasath D, Abeyasinghe R, Sibley CH, McCarthy J, von Seidlein L, Baird JK, Price RN.

Malar J. 2017 Apr 5;16(1):141. doi: 10.1186/s12936-017-1784-1. Review.

9.

G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications.

Luzzatto L, Seneca E.

Br J Haematol. 2014 Feb;164(4):469-80. doi: 10.1111/bjh.12665. Epub 2013 Dec 28. Review.

10.

Primaquine for reducing Plasmodium falciparum transmission.

Graves PM, Gelband H, Garner P.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD008152. doi: 10.1002/14651858.CD008152.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(6):CD008152.

PMID:
22972117
11.

Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine.

Galappaththy GN, Tharyan P, Kirubakaran R.

Cochrane Database Syst Rev. 2013 Oct 26;(10):CD004389. doi: 10.1002/14651858.CD004389.pub3. Review.

PMID:
24163057
12.

Diagnosis and treatment of Plasmodium vivax malaria.

Baird KJ, Maguire JD, Price RN.

Adv Parasitol. 2012;80:203-70. doi: 10.1016/B978-0-12-397900-1.00004-9. Review.

PMID:
23199489
13.

Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes.

Monteiro WM, Franca GP, Melo GC, Queiroz AL, Brito M, Peixoto HM, Oliveira MR, Romero GA, Bassat Q, Lacerda MV.

Malar J. 2014 Feb 25;13:70. doi: 10.1186/1475-2875-13-70. Review.

14.

Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report.

von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, Baird K, Moyes C, Howes R, Ménard D, Bancone G, Winasti-Satyahraha A, Vestergaard LS, Green J, Domingo G, Yeung S, Price R.

Malar J. 2013 Mar 27;12:112. doi: 10.1186/1475-2875-12-112. Review.

15.

G6PD deficiency in Latin America: systematic review on prevalence and variants.

Monteiro WM, Val FF, Siqueira AM, Franca GP, Sampaio VS, Melo GC, Almeida AC, Brito MA, Peixoto HM, Fuller D, Bassat Q, Romero GA, Maria Regina F O, Marcus Vinícius G L.

Mem Inst Oswaldo Cruz. 2014 Aug;109(5):553-68. Epub 2014 Aug 19. Review.

16.

Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission.

Graves PM, Gelband H, Garner P.

Cochrane Database Syst Rev. 2014 Jun 30;(6):CD008152. doi: 10.1002/14651858.CD008152.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;(2):CD008152.

17.

Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.

Graves PM, Gelband H, Garner P.

Cochrane Database Syst Rev. 2015 Feb 19;(2):CD008152. doi: 10.1002/14651858.CD008152.pub4. Review.

18.

Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common.

White NJ, Qiao LG, Qi G, Luzzatto L.

Malar J. 2012 Dec 14;11:418. doi: 10.1186/1475-2875-11-418. Review.

19.

Primaquine in vivax malaria: an update and review on management issues.

Fernando D, Rodrigo C, Rajapakse S.

Malar J. 2011 Dec 12;10:351. doi: 10.1186/1475-2875-10-351. Review.

20.

Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax.

Thomas D, Tazerouni H, Sundararaj KG, Cooper JC.

Acta Trop. 2016 Aug;160:35-8. doi: 10.1016/j.actatropica.2016.04.009. Epub 2016 Apr 21. Review.

PMID:
27109040

Supplemental Content

Support Center